Agilent Technologies Inc (NYSE:A) – Equities researchers at Svb Leerink upped their FY2019 earnings estimates for shares of Agilent Technologies in a research note issued on Wednesday, August 14th, Zacks Investment Research reports. Svb Leerink analyst P. Souda now expects that the medical research company will post earnings of $3.08 per share for the year, up from their previous estimate of $3.04. Svb Leerink also issued estimates for Agilent Technologies’ Q1 2020 earnings at $0.83 EPS, Q2 2020 earnings at $0.79 EPS, Q3 2020 earnings at $0.85 EPS, Q4 2020 earnings at $0.95 EPS, FY2020 earnings at $3.42 EPS and FY2021 earnings at $3.79 EPS.
Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 14th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. Agilent Technologies had a return on equity of 20.00% and a net margin of 21.06%. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. Agilent Technologies’s revenue for the quarter was up 5.6% compared to the same quarter last year.
Other research analysts also recently issued reports about the company. Zacks Investment Research downgraded Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 price target for the company. in a research note on Monday, August 19th. Piper Jaffray Companies upped their price objective on Agilent Technologies from $83.00 to $86.00 and gave the stock an “overweight” rating in a research note on Thursday, August 15th. Robert W. Baird reissued an “outperform” rating and issued a $82.00 price objective (up previously from $79.00) on shares of Agilent Technologies in a report on Thursday, August 15th. Deutsche Bank lowered their target price on shares of Agilent Technologies from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 15th. Finally, Needham & Company LLC upped their price target on shares of Agilent Technologies to $92.00 and gave the stock a “buy” rating in a research report on Monday, August 19th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $84.77.
Shares of NYSE A traded up $2.22 during mid-day trading on Monday, hitting $76.99. The company had a trading volume of 2,653,561 shares, compared to its average volume of 2,334,036. The firm has a 50-day simple moving average of $70.28 and a two-hundred day simple moving average of $73.97. Agilent Technologies has a one year low of $61.01 and a one year high of $82.27. The company has a current ratio of 2.13, a quick ratio of 1.72 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $22.96 billion, a PE ratio of 27.59, a price-to-earnings-growth ratio of 2.05 and a beta of 1.40.
Several hedge funds and other institutional investors have recently modified their holdings of A. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in Agilent Technologies by 81.0% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 157,403 shares of the medical research company’s stock valued at $11,753,000 after acquiring an additional 70,426 shares during the last quarter. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in Agilent Technologies during the 2nd quarter worth about $194,000. Toronto Dominion Bank raised its position in shares of Agilent Technologies by 55.1% in the 2nd quarter. Toronto Dominion Bank now owns 354,434 shares of the medical research company’s stock worth $26,461,000 after acquiring an additional 125,847 shares in the last quarter. Atria Investments LLC bought a new position in shares of Agilent Technologies in the 2nd quarter worth about $3,412,000. Finally, Nomura Holdings Inc. lifted its stake in shares of Agilent Technologies by 47.1% in the 2nd quarter. Nomura Holdings Inc. now owns 420,000 shares of the medical research company’s stock valued at $31,828,000 after purchasing an additional 134,558 shares during the period.
In other news, Director Heidi Fields sold 4,000 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $70.96, for a total value of $283,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.